Loading patent…
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite De Rennes 1, Centre Eugene Marquis, Enios Applications Private Limited Company
InventorsEric CHEVET, Tony AVRIL, Aristotelis CHATZIIOANNOU
Estimating the term…
The present invention relates to method of therapy selection for patient suffering from glioblastoma. Using in vitro and in vivo approaches, the inventors demonstrated the critical role of CD90 in GBM migration/invasion. They showed that CD90 signaling though SRC, FAK and RhoA promotes cell migration and importantly, that high CD90 expression impacts on the cell response to the SRC inhibitor dasatinib. In particular, the present invention relates to a method for predicting whether a subject will be eligible to a treatment with a drug selected from the group consisting of SRC inhibitor, FAK inhibitor or RhoA inhibitor by determining the expression level of CD90 in a sample obtained from the subject.
A method for predicting whether a subject will be eligible for treatment with a drug selected from the group consisting of SRC inhibitor, FAK inhibitor and RhoA inhibitor comprising i) determining the expression level of CD90 in a sample obtained from the subject, ii) comparing the expression level determined a step i) with a predetermined reference level and iii) and concluding that the subject will be eligible for the treatment when the expression level determined at step i) is higher than the predetermined reference level or concluding that the subject will not be eligible for the treatment when the expression level determined at step i) is lower that the predetermined expression level.
(canceled)
Dependencies are inferred from the claim text.